These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 30292795)
1. Bispecific anti-mPDGFRβ x cotinine scFv-C Kim S; Kim H; Jo DH; Kim JH; Kim SR; Kang D; Hwang D; Chung J Methods; 2019 Feb; 154():125-135. PubMed ID: 30292795 [TBL] [Abstract][Full Text] [Related]
2. Corrigendum to "Bispecific anti-mPDGFRβ x cotinine scFv-Cκ-scFv fusion protein and cotinine-duocarmycin can form antibody-drug conjugate-like complexes that exert cytotoxicity against mPDGFRβ expressing cells" [Methods 154 (2019) 125-135]. Kim S; Kim H; Jo DH; Kim JH; Kim SR; Kang D; Hwang D; Chung J Methods; 2019 Jul; 164-165():122. PubMed ID: 31320194 [No Abstract] [Full Text] [Related]
3. An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations. Jin J; Park G; Park JB; Kim S; Kim H; Chung J Exp Mol Med; 2018 May; 50(5):1-14. PubMed ID: 29795377 [TBL] [Abstract][Full Text] [Related]
4. A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer. Zong HF; Li X; Han L; Wang L; Liu JJ; Yue YL; Chen J; Ke Y; Jiang H; Xie YQ; Zhang BH; Zhu JW Acta Pharmacol Sin; 2024 Aug; 45(8):1727-1739. PubMed ID: 38605180 [TBL] [Abstract][Full Text] [Related]
5. Improved Lysosomal Trafficking Can Modulate the Potency of Antibody Drug Conjugates. DeVay RM; Delaria K; Zhu G; Holz C; Foletti D; Sutton J; Bolton G; Dushin R; Bee C; Pons J; Rajpal A; Liang H; Shelton D; Liu SH; Strop P Bioconjug Chem; 2017 Apr; 28(4):1102-1114. PubMed ID: 28151644 [TBL] [Abstract][Full Text] [Related]
6. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts. Yoon S; Kim YH; Kang SH; Kim SK; Lee HK; Kim H; Chung J; Kim IH J Cancer Res Clin Oncol; 2014 Feb; 140(2):227-33. PubMed ID: 24292501 [TBL] [Abstract][Full Text] [Related]
7. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. Herbener P; Schönfeld K; König M; Germer M; Przyborski JM; Bernöster K; Schüttrumpf J PLoS One; 2018; 13(4):e0195823. PubMed ID: 29672587 [TBL] [Abstract][Full Text] [Related]
8. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698 [TBL] [Abstract][Full Text] [Related]
9. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853 [TBL] [Abstract][Full Text] [Related]
10. Unlocking the potential of bispecific ADCs for targeted cancer therapy. Zeng H; Ning W; Liu X; Luo W; Xia N Front Med; 2024 Aug; 18(4):597-621. PubMed ID: 39039315 [TBL] [Abstract][Full Text] [Related]
11. Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design. Lee NK; Su Y; Bidlingmaier S; Liu B Mol Cancer Ther; 2019 Jun; 18(6):1092-1103. PubMed ID: 30962321 [TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry. Hong Y; Nam SM; Moon A Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356 [TBL] [Abstract][Full Text] [Related]
13. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations. Shim H Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076 [TBL] [Abstract][Full Text] [Related]
14. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
15. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification. Kim H; Park S; Lee HK; Chung J Exp Mol Med; 2013 Sep; 45(9):e43. PubMed ID: 24071736 [TBL] [Abstract][Full Text] [Related]
16. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day]. Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964 [TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096 [TBL] [Abstract][Full Text] [Related]
18. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors. Patrick TA; Kranz DM; Zachary JF; Roy EJ Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136 [TBL] [Abstract][Full Text] [Related]
19. Generation of a Novel SORT1×HER2 Bispecific Antibody-Drug Conjugate Targeting HER2-Low-Expression Tumor. Zhuang W; Zhang W; Wang L; Xie L; Feng J; Zhang B; Hu Y Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003245 [TBL] [Abstract][Full Text] [Related]
20. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology. Mihăilă RG Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]